Biotech Values

[DewDiligence]

I’m looking forward to hearing about ACHN’s HCV program whose compounds have an MoA so novel that the MoA couldn’t be disclosed. I think management’s handling of investor expectations with respect to this program has been silly, and this has (IMO) lowered management’s credibility, which wasn’t that high to begin with.

From today’s PR:

…the Company will provide an update on partnering efforts related to its non-HCV assets, elvucitabine and ACH-702.

If the update is that ACHN plans to spend even a dime of its own money on these programs, that would be bearish, IMO.